ANTX
AN2 Therapeutics, Inc. · Healthcare · Market cap $184.2M
Insiders sold $331K net in the last 90 days ·3 sellers, 1 buyer· 4 of 6 sales under Rule 10b5-1 plans· latest Form 4 filed Sep 11, 2026
Insider Buying
$12K
reported purchases (SEC code P)
Insider Selling
$398K
reported sales (SEC code S)
Unique Insiders
7
in the rolling window
Latest filing
Sep 16, 2026
Readnour Robin Shane
AN2 Therapeutics, Inc. (ANTX) has 33 SEC Form 4 filings (42 transaction rows) in the rolling window, disclosed by 7 distinct insiders. Most recent filing: Sep 16, 2026.
Inside the rolling window, 7 insiders at AN2 Therapeutics, Inc. reported 1 open-market purchase totaling $12K and 18 open-market sales totaling $398K. The most active filer is Director Readnour Robin Shane with 4 filings. Insiders have net sold $333K over the trailing 6 months. The most recent open-market filing is a sale of 1,108 shares by Director Readnour Robin Shane, dated Sep 9, 2026, worth $7K.
- Industry:Biotechnology
- CEO:Eric E. Easom
- Employees:21
- HQ:Menlo Park, CA, US
- IPO:2022-03-25
| Source | |||||||
|---|---|---|---|---|---|---|---|
| Director | Sale | 1,108 | $7K | Sep 11 | -9.8% | SEC ↗ | |
| Director | Sale | 6,100 | $37K | Sep 8 | -18.4% | SEC ↗ | |
| Director | Sale | 10,019 | $60K | Sep 8 | -18.4% | SEC ↗ | |
Williams Sarah JoanneFirst in 3 months | Principal Accounting Officer | Sale | 272 | $2K | Sep 4 | -17.1% | SEC ↗ |
FitzPatrick Margaret MFirst filing | Director | Purchase | 2,098 | $12K | Sep 2 | -18.0% | SEC ↗ |
Readnour Robin ShaneFirst filing | Director | Sale | 35,402 | $213K | Aug 19 | -18.1% | SEC ↗ |
Eizen Joshua MFirst in 6 months | See Remarks | Sale | 5,945 | $25K | Jul 10 | — | SEC ↗ |
| Principal Accounting Officer | Sale | 265 | $1K | Jun 2 | — | SEC ↗ | |
Williams Sarah JoanneFirst filing | Principal Accounting Officer | Sale | 327 | $347 | Mar 5 | — | SEC ↗ |
| See Remarks | Sale | 17,923 | $18K | Jan 7 | — | SEC ↗ | |
| See Remarks | Sale | 6,931 | $7K | Jan 7 | — | SEC ↗ | |
| Chief Strategy Officer | Sale | 3,604 | $4K | Jan 7 | — | SEC ↗ | |
| Chief Strategy Officer | Sale | 2,858 | $3K | Jan 7 | — | SEC ↗ | |
Day LucyFirst filing | Chief Financial Officer | Sale | 3,295 | $3K | Jan 7 | — | SEC ↗ |
Day LucyFirst filing | Chief Financial Officer | Sale | 5,512 | $6K | Jan 7 | — | SEC ↗ |
Chanda SanjayFirst filing | Chief Development Officer | Sale | 3,295 | $3K | Jan 7 | — | SEC ↗ |
Chanda SanjayFirst filing | Chief Development Officer | Sale | 5,956 | $6K | Jan 7 | — | SEC ↗ |
Eizen Joshua MFirst filing | See Remarks | Sale | 2,819 | $3K | Nov 6 | — | SEC ↗ |
Prior Stephen DavidFirst filing | Chief Strategy Officer | Sale | 765 | $872 | Nov 6 | — | SEC ↗ |
Frequently asked questions
How many SEC Form 4 insider filings does ANTX have?
AN2 Therapeutics, Inc. (ANTX) has 33 SEC Form 4 filings (42 transaction rows) in the rolling 365-day window, disclosed by 7 distinct insiders. Most recent filing: Sep 16, 2026.
When was the most recent SEC Form 4 filing for ANTX?
The most recent Form 4 filing for ANTX on Tracefour is dated Sep 16, 2026.
Who is the most active insider at ANTX?
The most active SEC Form 4 filer at ANTX in the rolling window is Director Readnour Robin Shane, with 4 filings.
What is the net insider flow at ANTX over the last 6 months?
Over the trailing 180 days, insiders at ANTX have net sold $333K based on SEC Form 4 disclosures.
What is the total insider buy and sell value at ANTX in the current window?
Inside the rolling window, insiders at ANTX bought $12K and sold $398K based on SEC Form 4 filings.
Can I get alerts for ANTX insider trading?
Yes. Tracefour sends a free email when a new SEC Form 4 purchase or sale is filed at AN2 Therapeutics, Inc. (ANTX). Alerts are set per company from the page itself, there is no paid tier, and each email links to the original filing on SEC EDGAR.
Related companies
AN2 Therapeutics, Inc. is in the Healthcare sector.